WO2001021631A3 - Secreted proteins and uses thereof - Google Patents

Secreted proteins and uses thereof Download PDF

Info

Publication number
WO2001021631A3
WO2001021631A3 PCT/US2000/025982 US0025982W WO0121631A3 WO 2001021631 A3 WO2001021631 A3 WO 2001021631A3 US 0025982 W US0025982 W US 0025982W WO 0121631 A3 WO0121631 A3 WO 0121631A3
Authority
WO
WIPO (PCT)
Prior art keywords
tango
polypeptides
nucleic acid
transmembrane
encodes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/025982
Other languages
French (fr)
Other versions
WO2001021631A2 (en
Inventor
Susan J Kirst
John D Sharp
Christopher C Fraser
Thomas Barnes
Gillian Kingsbury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Priority to EP00965288A priority Critical patent/EP1218411A4/en
Priority to AU76024/00A priority patent/AU7602400A/en
Publication of WO2001021631A2 publication Critical patent/WO2001021631A2/en
Publication of WO2001021631A3 publication Critical patent/WO2001021631A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides isolated INTERCEPT 307, MANGO 511, TANGO 351, TANGO 361, TANGO 499 AND TANGO 509, nucleic acid molecules and polypeptide molecules. INTERCEPT 307 encodes a transmembrane polypeptide related to the prostate cancer upregulated PB36 gene product. MANGO 511 encodes transmembrane polypeptides related to the leukocyte Ig-like receptors (LIRs). TANGO 351 encodes a transmembrane polypeptide that is involved in signaling. TANGO 499 variants encode secreted polypeptides related to glial cell line-derived neurotrophic factor (GDNF)-like polypeptides. Human and mouse TANGO 509 encode transmembrane polypeptides that contain immunoglobulin domains. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
PCT/US2000/025982 1999-09-20 2000-09-20 Secreted proteins and uses thereof Ceased WO2001021631A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00965288A EP1218411A4 (en) 1999-09-20 2000-09-20 Secreted proteins and uses thereof
AU76024/00A AU7602400A (en) 1999-09-20 2000-09-20 Secreted proteins and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39972399A 1999-09-20 1999-09-20
US09/399,723 1999-09-20

Publications (2)

Publication Number Publication Date
WO2001021631A2 WO2001021631A2 (en) 2001-03-29
WO2001021631A3 true WO2001021631A3 (en) 2001-11-22

Family

ID=23580710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/025982 Ceased WO2001021631A2 (en) 1999-09-20 2000-09-20 Secreted proteins and uses thereof

Country Status (3)

Country Link
EP (1) EP1218411A4 (en)
AU (1) AU7602400A (en)
WO (1) WO2001021631A2 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2389722A1 (en) * 1999-11-09 2001-05-17 Human Genome Sciences, Inc. 15 human secreted proteins
EP1234031B2 (en) 1999-11-30 2021-11-24 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
WO2001094413A2 (en) 2000-06-06 2001-12-13 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EA010594B1 (en) * 2001-05-24 2008-10-30 Займодженетикс, Инк. Taci-immunoglobulin fusion proteins
KR101510065B1 (en) 2005-06-08 2015-04-07 다나-파버 캔서 인스티튜트 인크. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
JP5713377B2 (en) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート Natural antisense and non-coding RNA transcripts as drug targets
EP2370593B1 (en) 2008-11-28 2016-03-30 Emory University Methods for determining the efficacy of pd-1 antagonists
KR101829469B1 (en) 2008-12-04 2018-03-30 큐알엔에이, 인크. Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
MX2011005912A (en) 2008-12-04 2011-06-17 Opko Curna Llc Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf.
KR101866152B1 (en) 2008-12-04 2018-06-08 큐알엔에이, 인크. Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010093904A2 (en) 2009-02-12 2010-08-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2010093906A2 (en) * 2009-02-12 2010-08-19 Curna, Inc. Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
EP2408919B1 (en) 2009-03-16 2017-10-18 CuRNA, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
EP2408920B1 (en) 2009-03-17 2017-03-08 CuRNA, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
CN102459596B (en) 2009-05-06 2016-09-07 库尔纳公司 Treatment of Lipid Transport and Metabolism Gene-Associated Diseases by Inhibition of Natural Antisense Transcripts Targeting Lipid Transport and Metabolism Genes
WO2010129746A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
WO2010129861A2 (en) 2009-05-08 2010-11-11 Curna, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
WO2010135329A2 (en) 2009-05-18 2010-11-25 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CN102549158B (en) 2009-05-22 2017-09-26 库尔纳公司 By suppressing to treat the disease that TFE3 is related to IRS albumen 2 (IRS2) for transcription factor E3 (TFE3) natural antisense transcript
CA2764683A1 (en) 2009-05-28 2010-12-02 Joseph Collard Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
CN102612560B (en) 2009-06-16 2017-10-17 库尔纳公司 By suppressing to treat the related diseases of PON1 for the natural antisense transcript of PON1 (PON1)
JP5944311B2 (en) 2009-06-16 2016-07-05 クルナ・インコーポレーテッド Treatment of collagen gene-related diseases by suppression of natural antisense transcripts against collagen genes
US8859515B2 (en) 2009-06-24 2014-10-14 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
CA2765815A1 (en) 2009-06-26 2010-12-29 Opko Curna, Llc Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
US20120252869A1 (en) 2009-07-24 2012-10-04 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
JP6128848B2 (en) 2009-08-05 2017-05-17 クルナ・インコーポレーテッド Treatment of insulin gene (INS) -related diseases by suppression of natural antisense transcripts against the insulin gene (INS)
CA2770104C (en) 2009-08-11 2019-03-19 Opko Curna, Llc Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
WO2011022606A2 (en) 2009-08-21 2011-02-24 Curna, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
KR101892760B1 (en) 2009-08-25 2018-08-28 큐알엔에이, 인크. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
KR101802540B1 (en) 2009-09-25 2017-11-28 큐알엔에이, 인크. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
WO2011084455A2 (en) 2009-12-16 2011-07-14 Opko Curna, Llc. Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
JP6031356B2 (en) 2009-12-23 2016-11-24 カッパーアールエヌエー，インコーポレイテッド Treatment of uncoupling protein 2 (UCP2) -related diseases by inhibition of natural antisense transcripts against UCP2.
ES2661387T3 (en) 2009-12-23 2018-03-28 Curna, Inc. Treatment of diseases related to hepatocyte growth factor (hgf) by inhibition of the natural antisense transcript to hgf
US8962585B2 (en) 2009-12-29 2015-02-24 Curna, Inc. Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
KR101838305B1 (en) 2009-12-29 2018-03-13 큐알엔에이, 인크. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
DK2519632T3 (en) 2009-12-31 2018-07-23 Curna Inc TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2- (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
EP2521784B1 (en) 2010-01-04 2017-12-06 CuRNA, Inc. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
CN102822342B (en) 2010-01-06 2017-05-10 库尔纳公司 Treatment of Pancreatic Developmental Gene-Related Diseases by Inhibiting Natural Antisense Transcripts of Pancreatic Developmental Genes
US9200277B2 (en) 2010-01-11 2015-12-01 Curna, Inc. Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
CN102782135A (en) 2010-01-25 2012-11-14 库尔纳公司 Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1
WO2011103528A2 (en) 2010-02-22 2011-08-25 Opko Curna Llc Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
CA2795145C (en) 2010-04-02 2019-01-22 Curna, Inc. Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
KR101900962B1 (en) 2010-04-09 2018-09-20 큐알엔에이, 인크. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
WO2011139387A1 (en) 2010-05-03 2011-11-10 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI531370B (en) 2010-05-14 2016-05-01 可娜公司 Treatment of PAR4-related diseases by inhibiting PAR4 natural anti-strand transcript
CA2799207C (en) 2010-05-26 2019-03-26 Curna, Inc. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
RU2620978C2 (en) 2010-05-26 2017-05-30 Курна, Инк. Treatment of diseases associated with methionine sulfoxide reductase a (msra), by msra natural antisense transcript inhibition
KR101914309B1 (en) 2010-06-23 2018-11-02 큐알엔에이, 인크. Treatment of sodium channel voltage-gated, alpha subunit (scna) related diseases by inhibition of natural abtisense transcript to scna
NO2593547T3 (en) 2010-07-14 2018-04-14
CA2813901C (en) 2010-10-06 2019-11-12 Curna, Inc. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
JP6049623B2 (en) 2010-10-22 2016-12-21 カッパーアールエヌエー，インコーポレイテッド Treatment of IDUA-related diseases by inhibition of natural antisense transcripts to α-L-iduronidase (IDUA)
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
WO2012071238A2 (en) 2010-11-23 2012-05-31 Opko Curna Llc Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
RU2620980C2 (en) 2011-06-09 2017-05-30 Курна, Инк. Treatment of diseases associated with frataxin (fxn), by inhibiting natural antisense fxn transcript
US10583128B2 (en) 2011-09-06 2020-03-10 Curna, Inc. Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules
EP2825648B1 (en) 2012-03-15 2018-09-05 CuRNA, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046643A1 (en) * 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1053252A1 (en) * 1998-02-11 2000-11-22 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
EP1056764A4 (en) * 1998-02-18 2001-08-29 Genetics Inst Secreted proteins and polynucleotides encoding them
EP1396543A3 (en) * 1999-07-08 2004-03-31 Research Association for Biotechnology Primers for synthesizing full length cDNA clones and their use
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046643A1 (en) * 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] THE INSTITUTE FOR GENOMIC RESEACH, (ROCKVILLE, MD, USA); 6 March 1999 (1999-03-06), ZHAO ET AL.: "Use of BAC end sequences from CalTech libraries for sequence-ready map building", XP002939272, accession no. STN Database accession no. AQ395363 *
DATABASE GENBANK [online] THE INSTITUTE FOR GENOMIC RESEARCH, (ROCKVILLE, MD, USA); 24 January 1999 (1999-01-24), ZHAO ET AL.: "Use of BAC end sequences from CalTech libraries for sequence-ready map building", XP002939275, accession no. STN Database accession no. AQ353657 *
DATABASE GENBANK [online] THE INSTITUTE FOR GENOMIC RESEARCH, (ROCKVILLE, MD, USA); 7 May 1999 (1999-05-07), ZHAO ET AL.: "Use of BAC end sequences from library RPCI-11 for sequence-ready map building", XP002939276, accession no. STN Database accession no. AQ350855 *
DATABASE MEDLINE [online] 8 August 1997 (1997-08-08), HILLIER ET AL.: "Generation and analysis of 280,000 human expressed sequence tags", XP002939273, accession no. STN Database accession no. AA399416 *
DATABASE MEDLINE [online] 8 August 1997 (1997-08-08), HILLIER ET AL.: "Generation and analysis of 280,000 human expressed sequence tags", XP002939274, accession no. STN Database accession no. AA292201 *
DATABASE MEDLINE [online] THE INSTITUTE FOR GENOMIC RESEARCH, (ROCKVILLE, MD, USA); 14 May 1997 (1997-05-14), HILLIER ET AL.: "Generation and analysis of 280,000 human expressed sequence tags", XP002939271, accession no. STN Database accession no. AA127696 *
GENOME RES., vol. 6, no. 9, 1996, pages 807 - 828 *
See also references of EP1218411A4 *

Also Published As

Publication number Publication date
AU7602400A (en) 2001-04-24
WO2001021631A2 (en) 2001-03-29
EP1218411A2 (en) 2002-07-03
EP1218411A4 (en) 2004-09-01

Similar Documents

Publication Publication Date Title
AU6063500A (en) Glycoprotein vi and uses thereof
DE60033293D1 (en) NEW B7-4 MOLECULES AND THEIR USES
WO1999066025A3 (en) Mtbx protein and nucleic acid molecules and uses therefor
WO1999055868A3 (en) Fizz proteins
ATE353965T1 (en) RECEPTORS COUPLED TO G-PROTEIN AND THEIR USES
EP1009752A4 (en) Novel molecules of the tango-77 related protein family and uses thereof
WO2002070652A3 (en) Novel molecules of the card-related protein family and uses thereof
ATE419358T1 (en) METHOD OF USE OF A NEW LYSYLOXIDASE-RELATED PROTEIN
WO2000052047A3 (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
WO2001000826A3 (en) Novel molecules of the card-related protein family and uses thereof
WO2000046236A3 (en) Novel rgs-containing molecules and uses thereof
WO2000039149A3 (en) Secreted proteins and uses thereof
ATE342979T1 (en) 15571, A NEW GPCR-LIKE MOLECULE OF THE SECRETIN-LIKE FAMILY AND ITS USES
EP1710299A3 (en) Secreted proteins and nucleic acids encoding them
WO2001061005A3 (en) Molecules of the pyrin domain protein family and uses thereof
CA2370666C (en) A tenascin-c isoform as a marker for neoplasias
WO2001000673A8 (en) Membrane-associated and secreted proteins and uses thereof
WO2000012544A3 (en) Novel irap-bp polypeptide and nucleic acid molecules and uses therefor
WO2002061049A3 (en) Novel molecules of the pyrin/nbs/lrr protein family and uses thereof
WO2000008045A3 (en) Novel molecules of the tango-93-related protein family and uses thereof
WO2001030971A3 (en) Novel molecules and the card-related protein family and uses thereof
WO2002085939A8 (en) Novel molecules of the card-related protein family and uses thereof
CA2218755A1 (en) Monoclonal antibody to human beta 2 integrin alpha subunit
WO2001023523A3 (en) Secreted proteins and uses thereof
WO2000018890A3 (en) Protein phosphatase molecules and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000965288

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000965288

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000965288

Country of ref document: EP